Cytek Biosciences (CTKB) Return on Capital Employed (2021 - 2026)

Cytek Biosciences has reported Return on Capital Employed for 6 years, with the latest figure at 11.72% in Q1 2026.

• For the quarter ending Q1 2026, Return on Capital Employed fell 587.0% year-over-year to 11.72%; the trailing twelve-month figure through Mar 2026 stood at 11.72% (down 587.0% YoY), and the FY2025 full-year result was 10.03%, down 525.0% from the prior year.
• Return on Capital Employed for Q1 2026 stood at 11.72%, down from 10.09% in the prior quarter.
• The five-year high for Return on Capital Employed was 1.31% in Q1 2022, with the low at 11.72% in Q1 2026.
• Historically, Return on Capital Employed has averaged 4.82% across 5 years, with a median of 5.85% in 2025.
• Annual changes were most pronounced in 2024 — Return on Capital Employed surged 138 bps — and 2026, when it plunged 587 bps.
• Cytek Biosciences' Return on Capital Employed stood at 0.39% in 2022, then tumbled by 1477 bps to 6.18% in 2023, then rose by 22 bps to 4.8% in 2024, then plunged by 110 bps to 10.09% in 2025, then dropped by 16 bps to 11.72% in 2026.
• The last three Return on Capital Employed figures came in at 11.72% (Q1 2026), 10.09% (Q4 2025), and 7.59% (Q3 2025), per Business Quant data.